Rafferty Asset Management’s Cytokinetics CYTK Stock Holding History

Rafferty Asset Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.69M	Sell	43,297 -29,310	-40%	-$2.1M	0.01%	446
2026 Q1	$4.79M	Sell	72,607 -25,934	-26%	-$1.65M	0.02%	382
2025 Q4	$6.26M	Sell	98,541 -5,567	-5%	-$346K	0.02%	359
2025 Q3	$5.72M	Sell	104,108 -67,473	-39%	-$2.78M	0.02%	396
2025 Q2	$5.67M	Buy	171,581 +22,074	+15%	+$768K	0.02%	372
2025 Q1	$6.01M	Sell	149,507 -18,428	-11%	-$847K	0.03%	330
2024 Q4	$7.9M	Sell	167,935 -48,891	-23%	-$2.54M	0.03%	324
2024 Q3	$11.4M	Sell	216,826 -48,243	-18%	-$2.69M	0.04%	265
2024 Q2	$14.4M	Buy	265,069 +125,592	+90%	+$7.58M	0.05%	217
2024 Q1	$9.78M	Sell	139,477 -123,798	-47%	-$9.57M	0.04%	273
2023 Q4	$22M	Buy	263,275 +16,353	+7%	+$592K	0.09%	132
2023 Q3	$7.27M	Buy	246,922 +22,498	+10%	+$749K	0.04%	307
2023 Q2	$7.32M	Buy	224,424 +33,270	+17%	+$1.23M	0.04%	324
2023 Q1	$6.73M	Sell	191,154 -34,223	-15%	-$1.4M	0.05%	305
2022 Q4	$10.3M	Buy	225,377 +98,277	+77%	+$4.23M	0.09%	175
2022 Q3	$6.16M	Buy	127,100 +30,443	+31%	+$1.47M	0.07%	278
2022 Q2	$3.8M	Sell	96,657 -45,945	-32%	-$1.85M	0.04%	342
2022 Q1	$5.25M	Sell	142,602 -3,466	-2%	-$123K	0.03%	381
2021 Q4	$6.66M	Buy	146,068 +40,511	+38%	+$1.56M	0.04%	273
2021 Q3	$3.77M	Sell	105,557 -18,424	-15%	-$542K	0.03%	382
2021 Q2	$2.45M	Sell	123,981 -22,020	-15%	-$517K	0.02%	615
2021 Q1	$3.4M	Buy	146,001 +106,276	+268%	+$2.27M	0.02%	407
2020 Q4	$825K	Sell	39,725 -31,392	-44%	-$574K	0.01%	562
2020 Q3	$1.54M	Buy	71,117 +49,344	+227%	+$1.15M	0.02%	487
2020 Q2	$513K	Buy	+21,773	New	+$408K	0.01%	703
2020 Q1	–	Sell	-47,996	Closed	-$509K	–	648
2019 Q4	$509K	Sell	47,996 -24,648	-34%	-$253K	0.01%	684
2019 Q3	$827K	Sell	72,644 -787	-1%	-$9.88K	0.01%	579
2019 Q2	$826K	Buy	73,431 +24,680	+51%	+$238K	0.01%	596
2019 Q1	$394K	Buy	+48,751	New	+$358K	0.01%	701

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Rafferty Asset Management's CYTK Position: Q2 2026 in Review

Rafferty Asset Management reduced its Cytokinetics (CYTK) stake by 40% in Q2 2026, selling an estimated $2.1M and leaving 43,297 shares worth $3.69M. The position accounts for 0.01% of the portfolio, ranked #446.

Rafferty Asset Management first reported a position in CYTK in Q1 2019 and has held it in 29 quarters since. The position peaked at $22M in Q4 2023. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Rafferty Asset Management held 43,297 shares of Cytokinetics worth $3.69M as of Q2 2026.
Rafferty Asset Management sold 29,310 Cytokinetics shares in Q2 2026, an estimated $2.1M.
Cytokinetics made up 0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #446 holding.
Rafferty Asset Management first reported a position in Cytokinetics in Q1 2019 and has held it in 29 quarters since.
Rafferty Asset Management's Cytokinetics position peaked at $22M in Q4 2023.
482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.